Literature DB >> 28196588

IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?

Romina E Araya1, Romina S Goldszmid2.   

Abstract

Type I interferons have been shown to play a major role in anti-cancer immunity. In this issue of Cancer Cell, Katlinski et al. describe tumor-induced degradation of type I interferon receptor IFNAR1 chain as a new immune-evasion mechanism in colorectal cancers. Stabilizing IFNAR1 inhibits tumor growth and improves immunotherapy efficacy. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28196588      PMCID： PMC7886182          DOI： 10.1016/j.ccell.2017.01.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

2.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

3.  Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Authors:  Antonella Sistigu; Takahiro Yamazaki; Erika Vacchelli; Kariman Chaba; David P Enot; Julien Adam; Ilio Vitale; Aicha Goubar; Elisa E Baracco; Catarina Remédios; Laetitia Fend; Dalil Hannani; Laetitia Aymeric; Yuting Ma; Mireia Niso-Santano; Oliver Kepp; Joachim L Schultze; Thomas Tüting; Filippo Belardelli; Laura Bracci; Valentina La Sorsa; Giovanna Ziccheddu; Paola Sestili; Francesca Urbani; Mauro Delorenzi; Magali Lacroix-Triki; Virginie Quidville; Rosa Conforti; Jean-Philippe Spano; Lajos Pusztai; Vichnou Poirier-Colame; Suzette Delaloge; Frederique Penault-Llorca; Sylvain Ladoire; Laurent Arnould; Joanna Cyrta; Marie-Charlotte Dessoliers; Alexander Eggermont; Marco E Bianchi; Mikael Pittet; Camilla Engblom; Christina Pfirschke; Xavier Préville; Gilles Uzè; Robert D Schreiber; Melvyn T Chow; Mark J Smyth; Enrico Proietti; Fabrice André; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2014-10-26       Impact factor: 53.440

Review 4.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

5.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.

Authors:  Bradley N Bidwell; Clare Y Slaney; Nimali P Withana; Sam Forster; Yuan Cao; Sherene Loi; Daniel Andrews; Thomas Mikeska; Niamh E Mangan; Shamith A Samarajiwa; Nicole A de Weerd; Jodee Gould; Pedram Argani; Andreas Möller; Mark J Smyth; Robin L Anderson; Paul J Hertzog; Belinda S Parker
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

6.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.

Authors:  Mercedes B Fuertes; Aalok K Kacha; Justin Kline; Seng-Ryong Woo; David M Kranz; Kenneth M Murphy; Thomas F Gajewski
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

7.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Authors:  Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

8.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

9.  Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury.

Authors:  Sabyasachi Bhattacharya; Kanstantsin V Katlinski; Maximilian Reichert; Shigetsugu Takano; Angela Brice; Bin Zhao; Qiujing Yu; Hui Zheng; Christopher J Carbone; Yuliya V Katlinskaya; N Adrian Leu; Kelly A McCorkell; Satish Srinivasan; Melanie Girondo; Hallgeir Rui; Michael J May; Narayan G Avadhani; Anil K Rustgi; Serge Y Fuchs
Journal:  EMBO Mol Med       Date:  2014-01-30       Impact factor: 12.137

10.  Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration.

Authors:  Markus Tschurtschenthaler; Jun Wang; Cornelia Fricke; Teresa M J Fritz; Lukas Niederreiter; Timon E Adolph; Edina Sarcevic; Sven Künzel; Felix A Offner; Ulrich Kalinke; John F Baines; Herbert Tilg; Arthur Kaser
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059
  10 in total
  10 in total

1.  Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon.

Authors:  Shuhong Han; Haoyang Zhuang; Pui Y Lee; Mingjia Li; Lijun Yang; Peter A Nigrovic; Westley H Reeves
Journal:  Arthritis Rheumatol       Date:  2019-12-10       Impact factor: 10.995

Review 2.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 3.  Flaming the fight against cancer cells: the role of microRNA-93.

Authors:  Milad Ashrafizadeh; Masoud Najafi; Reza Mohammadinejad; Tahereh Farkhondeh; Saeed Samarghandian
Journal:  Cancer Cell Int       Date:  2020-06-29       Impact factor: 5.722

Review 4.  Targeting Angiogenesis With Peptide Vaccines.

Authors:  Michal A Rahat
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

Review 5.  Type I interferons and endoplasmic reticulum stress in health and disease.

Authors:  Jenny Sprooten; Abhishek D Garg
Journal:  Int Rev Cell Mol Biol       Date:  2019-11-19       Impact factor: 6.813

6.  Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway.

Authors:  Kevin Alicea-Torres; Emilio Sanseviero; Jun Gui; Jinyun Chen; Filippo Veglia; Qiujin Yu; Laxminarasimha Donthireddy; Andrew Kossenkov; Cindy Lin; Shuyu Fu; Charles Mulligan; Brian Nam; Gregory Masters; Fred Denstman; Joseph Bennett; Neil Hockstein; Agnieszka Rynda-Apple; Yulia Nefedova; Serge Y Fuchs; Dmitry I Gabrilovich
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 14.919

7.  Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.

Authors:  Rui Sun; Pei-Pei Zhang; Xiang-Qin Weng; Xiao-Dong Gao; Chuan-Xin Huang; Li Wang; Xiao-Xia Hu; Peng-Peng Xu; Lin Cheng; Lu Jiang; Di Fu; Bin Qu; Yan Zhao; Yan Feng; Hong-Jing Dou; Zhong Zheng; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2022-03-18

Review 8.  MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis.

Authors:  Mohammad Reza Karimzadeh; Maryam Zarin; Naeim Ehtesham; Sharifeh Khosravi; Mohsen Soosanabadi; Meysam Mosallaei; Peyman Pourdavoud
Journal:  Cancer Gene Ther       Date:  2020-03-23       Impact factor: 5.987

Review 9.  Type I interferons and related pathways in cell senescence.

Authors:  Steven M Frisch; Ian P MacFawn
Journal:  Aging Cell       Date:  2020-09-12       Impact factor: 9.304

Review 10.  Deregulation of HLA-I in cancer and its central importance for immunotherapy.

Authors:  Ahmet Hazini; Kerry Fisher; Len Seymour
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.